What is the recommended dosing and administration schedule for durvalumab (durvalumab), gemcitabine, and cisplatin in a 79‑year‑old woman with metastatic perihilar cholangiocarcinoma participating in the TOPAZ‑1 trial, including renal function considerations and the option to substitute oxaliplatin if needed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

TOPAZ-1 Dosing Schedule for Durvalumab, Gemcitabine, and Cisplatin

The TOPAZ-1 regimen consists of durvalumab 1500 mg IV on day 1, gemcitabine 1000 mg/m² IV on days 1 and 8, and cisplatin 25 mg/m² IV on days 1 and 8, administered every 3 weeks for up to 8 cycles, followed by durvalumab 1500 mg IV monotherapy every 4 weeks until disease progression. 1, 2

Induction Phase (Cycles 1-8)

Each 21-day cycle includes:

  • Durvalumab: 1500 mg IV infusion on Day 1 only
  • Gemcitabine: 1000 mg/m² IV over 30 minutes on Days 1 and 8
  • Cisplatin: 25 mg/m² IV on Days 1 and 8 (administered after gemcitabine)

Continue this combination for a maximum of 8 cycles (24 weeks total). 3, 1

Maintenance Phase (After Cycle 8)

Following completion of chemotherapy:

  • Durvalumab monotherapy: 1500 mg IV every 4 weeks (28-day cycles)
  • Continue until disease progression, unacceptable toxicity, or other discontinuation criteria 3, 1

Critical Considerations for a 79-Year-Old Patient

Renal Function Assessment

For cisplatin eligibility, calculate creatinine clearance (CrCl):

  • CrCl ≥30 mL/min: Proceed with standard cisplatin dosing
  • CrCl <30 mL/min or borderline renal function: Consider oxaliplatin substitution 4, 5

The TOPAZ-1 trial specifically used cisplatin 25 mg/m² on days 1 and 8, which is a fractionated, lower-intensity schedule compared to traditional cisplatin 75-100 mg/m² every 3 weeks. This fractionated approach reduces nephrotoxicity risk while maintaining efficacy. 1

Oxaliplatin Substitution (If Needed)

If cisplatin is contraindicated due to renal impairment:

  • Oxaliplatin: 130 mg/m² IV on Day 1 only (not days 1 and 8)
  • Combine with gemcitabine 1000 mg/m² on days 1 and 8
  • This creates a modified "GEMOX" backbone with durvalumab 4, 6

Important caveat: The TOPAZ-1 trial did not include oxaliplatin substitution, so this represents extrapolation from biliary tract cancer guidelines showing gemcitabine-oxaliplatin activity. The survival benefit with durvalumab may differ from the proven TOPAZ-1 regimen. 4, 7, 5

Dose Modifications for Myelosuppression

On Day 1 of each cycle:

  • Hold treatment if ANC <1,500/µL or platelets <100,000/µL
  • Resume when counts recover 8

On Day 8 of each cycle (gemcitabine/cisplatin only):

  • ANC ≥1,200 AND platelets ≥75,000: Give 100% dose
  • ANC 1,000-1,199 OR platelets 50,000-75,000: Give 75% dose
  • ANC 700-999 AND platelets ≥50,000: Give 50% dose
  • ANC <700 OR platelets <50,000: Hold Day 8 doses 8

Durvalumab dosing does not require adjustment for hematologic toxicity—only hold if severe immune-related adverse events occur. 3

Monitoring Requirements

Before each cycle:

  • Complete blood count with differential
  • Comprehensive metabolic panel (renal and hepatic function)
  • Thyroid function tests (baseline and periodically)
  • Assessment for immune-related adverse events 3

Imaging:

  • CT chest/abdomen/pelvis every 6-9 weeks to assess response per RECIST 1.1 criteria 1

Key Safety Considerations

Permanently discontinue durvalumab for:

  • Grade 3-4 immune-related pneumonitis
  • Grade 4 immune-related hepatitis or AST/ALT >8x ULN
  • Grade 3-4 immune-related colitis
  • Any life-threatening immune-related adverse event 3

Common toxicities in TOPAZ-1:

  • Neutropenia (21% grade 3-4)
  • Anemia (19% grade 3-4)
  • Thrombocytopenia (less common than with traditional cisplatin schedules)
  • Immune-related adverse events occurred in 2.4% (grade 3-4) 1, 9

Age-Specific Considerations

At 79 years old, this patient falls within the TOPAZ-1 study population (age range 18-96 years). Pharmacokinetic studies show no clinically significant differences in durvalumab clearance based on age. 3 However, monitor closely for:

  • Cumulative cisplatin nephrotoxicity
  • Myelosuppression (may be more pronounced in elderly)
  • Immune-related adverse events (no age-related increase in incidence)

The fractionated cisplatin schedule (25 mg/m² days 1 and 8) used in TOPAZ-1 is better tolerated than traditional high-dose cisplatin, making it more appropriate for older patients. 1, 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.